Results 361 to 370 of about 192,309 (409)

Exposure to potentially teratogenic medications before and during the first trimester of pregnancy compared to women of childbearing age: A retrospective analysis of Swiss claims data (2015–2021)

Acta Obstetricia et Gynecologica Scandinavica, Volume 104, Issue 4, Page 707-719, April 2025.
In Switzerland, most dispensed medications with teratogenic effect debated or proven were in the group of weak teratogenicity level. Reassuringly, many women discontinue treatment with potential teratogens before pregnancy. Abstract Introduction Exposure to potentially teratogenic medications during pregnancy is underinvestigated in Switzerland.
Carole A. Marxer, Sereina M. Graber, Daniel Surbek, Alice Panchaud, Christoph R. Meier, Julia Spoendlin   +5 more
wiley   +1 more source

Application of rapid genotyping of Warfarin individualized pharmacogenetic variants in Warfarin therapy. [PDF]

Sci Rep
Huang D, Xie F, Xiao S, Cai M, Hu D, Ling B, Wang F, Lin X, Song F, Wang Q, Zhong T.   +10 more
europepmc   +1 more source

Safety of enoxaparin in patients implanted with continuous flow left ventricular assist devices

Artificial Organs, Volume 49, Issue 4, Page 639-648, April 2025.
There was no significant difference in major bleeding or thromboembolic events between patients who received enoxaparin 1 mg/kg every 12 h (LMWH) or intravenous unfractionated heparin (IV UFH) for bridging of a subtherapeutic INR 60 days after implantation of a CF‐LVAD.
Rachel C. Klosko, Bryan Whitson, Brent Lampert, Eric McLaughlin, Libby Orzel   +4 more
wiley   +1 more source

Nonbacterial Thrombotic Endocarditis of a Mitral Prosthesis After Warfarin, Enoxaparin, and Apixaban Failure. [PDF]

JACC Case Rep
Nevin A, Muallem S, Pfeiffer M.
europepmc   +1 more source

Direct Oral Anticoagulants for the Treatment of Unusual-Site Venous Thrombosis: An Update. [PDF]

Pharmaceutics
Franco-Moreno A, Madroñal-Cerezo E, Martínez-Casa-Muñoz A, Ortiz-Sánchez J, Ancos-Aracil CL.   +4 more
europepmc   +1 more source

The burden of atrial fibrillation and unmet needs of its management in Southeast Asia and South Asia. [PDF]

Lancet Reg Health Southeast Asia
Krittayaphong R, Kaolawanich Y, Phrommintikul A, Guruparan M, Subaschandran K, Bahuleyan CG, Namboodiri N, Lip GYH.   +7 more
europepmc   +1 more source

Impact of insurance coverage for non-vitamin K antagonist oral anticoagulants on quality of care and care disparities in patients hospitalised with atrial fibrillation in tertiary hospitals in China: interrupted time series analysis. [PDF]

BMJ Open
Yang N, Sun Z, Liu J, Hao Y, Long D, Zhao D, Liu J, CCC-AF Investigators.   +7 more
europepmc   +1 more source

Hemorrhage risk associated with triple antithrombotic therapy: a focused real-world pharmacovigilance disproportional analysis study. [PDF]

BMC Cardiovasc Disord
Sridharan K, Sivaramakrishnan G.
europepmc   +1 more source

Clinical effectiveness and safety comparison between direct oral anticoagulants and warfarin for nonvalvular atrial fibrillation patients following percutaneous left atrial appendage closure operation intervention: a prospective observational study. [PDF]

BMC Pharmacol Toxicol
Yao Y, Jin Q, Zhang X, Lv Q.
europepmc   +1 more source

Oral Abstracts for the 17th Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions

Journal of Arrhythmia, Volume 41, Issue 2, April 2025.
wiley   +1 more source